ArticleVirchows Archiv : an international journal of pathology2021
Desmoplastic myxoid tumor, SMARCB1-mutant: a new variant of SMARCB1-deficient tumor of the central nervous system preferentially arising in the pineal region.
Article in Virchows Archiv : an international journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Aggressive clinical behavior of desmoplastic myxoid tumor of the pineal region, SMARCB1-mutant: expanding the biological spectrum of a rare central nervous system neoplasm.Virchows Archiv : an international journal of pathology · 2026Article
- Desmoplastic myxoid tumor, SMARCB1-mutant: a case with late recurrence after long-term follow-up.Free neuropathology · 2026Article
- Pineal Gland Parenchyma Tumors.Advances and technical standards in neurosurgery · 2026Review
- Imaging of Pineal Region Masses.Advances and technical standards in neurosurgery · 2026Review
- Desmoplastic myxoid tumor of the pineal region, SMARCB1 mutant: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- A mass in the pineal region of a young woman.Brain pathology (Zurich, Switzerland) · 2024Article
- Newly Recognized CNS Tumors in the 2021 World Health Organization Classification: Imaging Overview with Histopathologic and Genetic Correlation.AJNR. American journal of neuroradiology · 2023Review
- Current Molecular and Clinical Landscape of ATRT - The Link to Future Therapies.Cancer management and research · 2023Review
- Pediatric Pineal Region Tumors: Special Reference to Posterior Interhemispheric Trans-Tentorial Approach.Advances and technical standards in neurosurgery · 2023Review
- Review
- Clinical management of desmoplastic myxoid tumor, SMARCB1-mutant.Neuro-oncology · 2022Article
- A case of an atypical teratoid/rhabdoid tumor with distinctive histology in the pineal region in an adult patient.Pathology international · 2021Review
- Desmoplastic myxoid tumor of pineal region, SMARCB1-mutant, in young adult.Free neuropathology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Desmoplastic myxoid tumor (DMT), SMARCB1-mutant is a recently proposed brain tumor that occurs in the pineal region of adults. This tumor is characterized by desmoplastic stroma and various degrees of myxoid matrix. Tumor cells with low-grade morphology show polyphenotypic immunoreactivity, and rhabdoid cells are rare. We herein present a case with some uncommon features such as no myxoid stroma and slightly elevated proliferating activity. To date, knowledge on the variety of SMARCB1/INI1-deficient tumors of the central nervous system is gradually increasing, encompassing highly aggressive to slow-growing varieties. DMT, SMARCB1-mutant seems to be relatively benign, but careful attention is necessary because SMARCB1/INI1 deficiency is generally a genetic signature of concern.
Indexed as
Identifiers
33420834What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.